In this episode of Topical Conversations, Heather Gates, PA-C, and Marc Serota, MD, explore the challenges and treatment strategies for patients with moderate atopic dermatitis (AD). They emphasize the importance of assessing patients accurately and highlight the evolving role of systemic therapies.
Understanding moderate atopic dermatitis: assessing the patient
Patients with moderate AD often present with fluctuating symptoms. They may appear well on the day of their visit but experience significant discomfort during flare-ups. According to Dr Serota, dermatologists must go beyond the snapshot of what they see in the office and dig deeper into the patient’s daily experience with the disease. Important factors to assess include:
These considerations often reveal that even if a patient seems to have mild symptoms in the office, their overall burden of disease is much more significant.
Transitioning from topicals to systemic therapies
Deciding when to transition from topical treatments to systemic options is crucial in AD management. As Heather Gates and Dr Serota explain, the availability of newer, safer systemic therapies has shifted the conversation.
Both Gates and Serota agree that every patient with AD should have a topical treatment available, particularly nonsteroidal options. This remains a staple of treatment regardless of whether the patient is on systemic therapy.
Historically, systemic treatments like methotrexate were avoided early in treatment plans, especially in pediatric cases. However, with the introduction of safer alternatives such as dupilumab, Dr Serota now initiates the conversation about systemic options early, even during the first visit for patients with moderate AD, noting that these patients deserve to be informed of all treatment options, and the decision on whether to start systemic therapy can be made collaboratively.
Choosing a systemic therapy
Selecting the right systemic therapy for moderate to severe AD depends on several factors, including the patient’s age, comorbid conditions, and the severity of their symptoms. Newer systemic therapies have provided safer alternatives to traditional treatments like methotrexate and cyclosporine, which were often associated with significant side effects.
Dr Serota highlights the utility of dupilumab for patients with comorbid conditions, noting that with its indications for associated atopic conditions, it can address skin symptoms as well as target related conditions such as asthma, making it a holistic treatment option for patients with multiple atopic diseases.
Communicating systemic treatment options to patients and parents
When discussing the possibility of systemic treatments, setting realistic expectations is critical. Gates and Serota emphasize the importance of framing the conversation in a way that is clear, reassuring, and rooted in long-term management.
Gates advises underselling the benefits and overdelivering. She stresses to parents that AD is a chronic disease, and the child will likely need long-term therapy. This helps prevent disappointment and encourages adherence.
Dr Serota uses simple analogies to help explain systemic treatments. For example, he compares dupilumab to a radio signal blocker that specifically targets allergic cells, avoiding broad immunosuppression. He also compares the injection schedule to that of diabetes treatments, explaining that the infrequent administration (every two weeks or once a month) is manageable compared to daily insulin injections.
Systemic therapy for moderate AD: a shift in treatment paradigms
With advances in systemic therapies, the approach to treating moderate atopic dermatitis has shifted dramatically. Dermatologists are now empowered to initiate conversations about systemic treatments earlier in the disease course, offering patients the chance to live with less itch, better sleep, and improved quality of life.
Even if patients choose not to proceed with systemic therapy, ensuring that they are aware of the benefits, risks, and availability of these treatments is essential for shared decision-making and better long-term outcomes.
In this 45-minute symposium, expert faculty cover the latest updates for JAK inhibitors, including head-to-head efficacy and safety data for JAK inhibitors and biologics, and share clinical pearls for using JAK inhibitors in dermatology practice for atopic dermatitis."I can say that in my clinic, I am reaching for those high bars. You have toput yourself in the position of the patient or imagine that patient is your family member. Would you want mediocre treatment for them or average treatment or moderate treatment? You’d want them to get the best possible treatment. In my practice I’m now counseling patients 'yes we want clear skin. Yes, we want minimal itch. Yes we want your skin pain gone and for you to sleep better.'”- David Cotter, MD, PhDFC25: Charting the Course to Higher Targets With JAK Inhibition in Atopic Dermatitis: An Online ActivityThis activity is supported by an educational grant from AbbVie.
Don’t miss this Satellite Symposium from the 2025 Fall Clinical Dermatology Conference®, as Dr. Alexandra Golant, Dr. Mona Shahriari, and Dr. G. Michael Lewitt discuss IL-13 targeting biologics in the treatment of atopic dermatitis as well as strategies for optimizing their use.“To me, coming into an exam room in 2025, when we have so many different treatment options for these patients, it's a unique opportunity to use what we know about the data of these therapeutics and walk patients though their options and how to understand their disease state, and how to best choose the therapy that feels right for them.” – Alexandra Golant, MD FC25: Illuminate the Role of IL-13 Inhibitors for the Management of Atopic DermatitisThis activity is supported by an educational grant from Lilly.
“Of course we’re always starting with our basics: we’re using our gentle cleansers, our moisturization, our avoidance of known allergens or triggers, and then we're doing our topicals. But it can be very difficult if you have heavy stuff on your face or you’re required to put it on over and over. It can be really tough. So this paves the way really nicely to say it is time to move up, it is time to think about the next level, and typically the next step up is going to be a biologic agent.” - Peter Lio, MDA ‘HowTo’ activity delivers a short burst of engaging and compact content for learners to study at their own convenience. This microlearning activity is intended to provide practical insights from two experts on ‘HowTo’ improve care in head and neck atopic dermatitis in 10 minutes.This activity is supported by an educational grant from LEO Pharma.
This 30-minute symposium from the 2025 Pediatrics360 Virtual Conference takes a closer look at biologic therapies that can address the immune pathophysiology, associated comorbidities, and progression of moderate-to-severe atopic dermatitis in pediatric patients.“A lot of them (children with atopic dermatitis) do have tactile sensitivities and don’t like the way any creams, ointments, anything, feel on their skin. Thinking about a shot, even though it hurts, doing a shot once or twice a month can actually often be so much easier than having the parents have to argue with the kid two to three times a day to get the topicals on. So, I actually think of injections very quickly for patients with tactile sensitivities.” – Dr. Elizabeth SwansonPEDS25: Controlling the Wolf in Sheep’s Clothing: Managing Pediatric Atopic Dermatitis with Biologic Therapies: An Online ActivityThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals, Inc.